Background: The 2019 novel coronavirus disease (COVID-19) has spread to more than 213 countries and as of 17 April 2020, 1,995,983 confirmed cases and 131,037 deaths have been reported globally. Pakistan sharing border with China and Iran, having a high frequency of travel and trade , has been at risk of viral transmission. Methods: We examined the current state of the COVID-19 epidemic and Pakistan's preparedness, using publicly available data and documents on the COVID-19 government dashboard.

We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established Vero cell platform to produce large-scale GMP grade highly purified inactivated antigen. Product development and manufacturing process were carried out in a BSL-3 facility. Immunogenicity and safety was determined at two antigen concentrations (3μg and 6μg), with two different adjuvants, in mice, rats and rabbits. Our results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers (NAb), at both concentrations, in all three species with excellent safety profiles. The inactivated vaccine formulation containing TLR7/8 agonist adjuvant-induced Th1 biased antibody responses with elevated IgG2a/IgG1 ratio and increased levels of SARS-CoV-2 specific IFN-γ + CD4 + T lymphocyte response. Our results support further development for Phase I/II clinical trials in humans.

We report the development and evaluation of safety and immunogenicity of a whole virion inactivated SARS-COV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or a novel TLR7/8 agonist adsorbed Algel. We used a well-characterized SARS-CoV-2 strain and an established vero cell platform to produce large-scale GMP grade highly purified inactivated antigen, BBV152. Product development and manufacturing were carried out in a BSL-3 facility. Immunogenicity was determined at two antigen concentrations (3μg and 6μg), with two different adjuvants, in mice, rats, and rabbits. Our results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers, at both concentrations, in all three species with excellent safety profiles. The inactivated vaccine formulation containing TLR7/8 agonist adjuvant-induced Th1 biased antibody responses with elevated IgG2a/IgG1 ratio and increased levels of SARS-CoV-2 specific IFN-γ+ CD4 T lymphocyte response. Our results support further development for Phase I/II clinical trials in humans.

No abstract

Electrical properties of edible oil depend upon its total polar component, temperature and the frequency of the applied voltage. Dielectric constant, dielectric loss tangent and electrical conductivity were measured for cottonseed (Gossypium sp.), ground nut (Apios americana), mustard (Brasicca compestriss) and sun flower (Helianthus annuus) oils in the temperature range of 20 to 100°C so as to assess the potential of their applicability for assessing the quality of oils. Viscosity of the oils is an other important physical property associated with their processing and quality control. Viscosity of these oils was experimentally measured. The correlation of viscosity with dielectric loss tangent and viscosity with electrical conductivity were tested. The best correlating relations along with correlation constants, valid for the temperature range of 20-100°C are presented. The regression equation developed relating viscosity with loss tangent and electrical conductivity had high correlation coefficient (R(2) > 0.96) for all the four oils within temperature range of 20-100°C.